Health Condition 1: L811- Chloasma
Conditions
Interventions
Intervention1: Glycolic acid (GA) peel with triple combination cream (TC): Glycolic Acid peel will be applied topically over face for 3-4 minutes and then washed with water. Peel will be done every tw
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with modified MASI score >5. 2. Patients in general good health. 3. Females of childbearing age will be on a reliable form of contraception during the course of treatment other than oral contraceptive pills or hormone intrauterine device. 4. Patients must be willing to sign consent, answer questionnaires, and comply with all clinical visits, and use sunscreen and sun-protection measures. 5. Patients must be willing to not apply other treatment options for melasma during the course of the study.
Exclusion criteria
Exclusion criteria: 1. Patients with known allergy to any components of the peel. 2. Patients on any concurrent therapy, concurrent illness, active or recurrent herpes labialis, keloidal tendencies, unrealistic expectations. 3. Pregnant and willing to be pregnant women, nursing mothers. 4. Patients who cannot communicate with investigators or who are unlikely to cooperate. 5. Patients who have been treated for melasma with any topical therapy in past 2 weeks or chemical peel in past 4 weeks. 6. Patients who have used micro derma abrasion or facial laser treatments in the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Change in pigmentation as seen by the effect on mMasi score at week 0, 6 and 12 2.Change in quality of life as seen by the effect on MELASQOL score at week 0 and 12.Timepoint: 1.Change in pigmentation as seen by the effect on mMasi score at week 0, 6 and 12 2.Change in quality of life as seen by the effect on MELASQOL score at week 0 and 12. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Reduction in mean mMASI score from week 0 to week 6 and 12. 2. Improvement in MELASQOL score from week 0 to week 12. 3. Adverse event assessment every 2 weeks till the end of treatment.Timepoint: 1. Reduction in mean mMASI score from week 0 to week 6 and 12. 2. Improvement in MELASQOL score from week 0 to week 12. 3. Adverse event assessment every 2 weeks till the end of treatment. | — |
Countries
India
Contacts
Public ContactDr Dhvani Chaudhary
Department of Dermatology,GMERS Medical College and Hospital
Outcome results
None listed